CSIMarket
 
Helius Medical Technologies inc   (HSDT)
Other Ticker:  
 
 
Price: $5.7100 $0.21 3.816%
Day's High: $5.885 Week Perf: -6.09 %
Day's Low: $ 5.44 30 Day Perf: -6.09 %
Volume (M): 8 52 Wk High: $ 14.44
Volume (M$): $ 47 52 Wk Avg: $8.14
Open: $5.89 52 Wk Low: $0.18



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 0

Helius Medical Technologies Inc
Helius Medical Technologies Inc. is a medical technology company specializing in the development and commercialization of non-invasive platform technologies used in the treatment of neurological symptoms caused by disease or trauma. Its flagship product, the Portable Neuromodulation Stimulator (PoNS), is a medical device designed to deliver neurostimulation through the tongue to enhance neuroplasticity in the brain. This innovative approach aims to improve symptoms related to neurodegenerative diseases, traumatic brain injuries, and other neurological disorders. The company is headquartered in Newton, Pennsylvania, and operates in both the United States and Canada.


   Company Address: 642 Newtown Yardley Road, Suite 100 Newtown 18940 PA
   Company Phone Number: 944-6100   Stock Exchange / Ticker: NASDAQ HSDT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

PoNS Therapy: A Paradigm Shift in Stroke Rehabilitation - Unveiling the Potential of Neuromodulation for Gait and Balance Improvement

Published Tue, Mar 12 2024 12:59 PM UTC

Neuromodulation Therapy Holds Promise for Stroke Rehabilitation: Open-Label Study Evaluating Portable Neuromodulation Stimulator Shows Encouraging Results in Improving Gait and BalanceStroke is a leading cause of long-term disability and physical impairment worldwide, affecting millions of individuals each year. Despite advancements in treatment and rehabilitation strategies...

Product Service News

Augmenting MS Treatment: Helius Medical Technologies Secures Reimbursement Milestone and Extends Financial Stability until 2024

Published Mon, Mar 4 2024 12:00 PM UTC

Helius Medical Technologies Secures Reimbursement Milestone for Revolutionary MS Treatment Device, Extends Financial Stability Until 2024In a significant development for the healthcare industry, Helius Medical Technologies, Inc. has successfully obtained HCPCS codes for their groundbreaking Portable Neuromodulation Stimulator (PoNS) Mouthpiece and Controller. This achievemen...

Product Service News

Helius Medical Technologies, Inc. Expands Stroke Program and Achieves Impressive Revenue Growth

Published Thu, Jan 11 2024 12:00 PM UTC

Helius Medical Technologies, Inc. Expands Stroke Program and Sees Significant Revenue IncreaseIn an exciting development, Helius Medical Technologies, Inc. has announced the expansion of its stroke clinical program with the addition of Brooks Rehabilitation Hospital. This collaboration adds a second site to the registrational program in stroke, bringing the total number of p...

Earnings announcement

Helius Medical Technologies, Inc Receives Letter of Intent from Québec Ministry of Health and Social Services to Purchase 30 PoNS Devices

Published Thu, Oct 12 2023 11:05 AM UTC

Helius Medical Technologies, Inc. Receives Letter of Intent from Québec Ministry of Health and Social Services to Purchase 30 PoNS Devices
Helius Medical Technologies, Inc., a leading neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, recently announced that it has received a letter of intent (LOI) from the Québec Ministry of Hea...

Helius Medical Technologies Inc

Helius Medical Technologies Inc. Reports a Narrowed Deficit and Promising Revenue Growth in Q1 2023 Earnings

In the first quarter of 2023 earnings season, Helius Medical Technologies Inc. reported a loss of $-0.09 per share, which was an improvement from the previous year's loss of $-2.01 per share. This is an important metric for investors as it indicates how much money the company is losing per share. The company's income per share also fell from $0.02 in the preceding quarter. This is a concern for investors as it indicates that the company's profits are decliningThe revenue of the company grew softly by 1.835% to $0.11 million from $0.11 million in the comparable quarter a year ago. This signifies that the company's revenue is slowly growing. However, sequentially, revenue tumbled by -73.381% from $0.42 million. This is a worrying sign for investors as it indicates that the company's revenue is declining rapidly.
Although the company did report a net deficit of $-2.494 million, which was an improvement from the previous year's deficit of $-4.687 million, investors may still be concerned about the company's financial performance. It is important to note that these numbers are just initial projections and may change as time goes on.
Investors should keep an eye on the company's future financial reports to see how it performs in the coming quarters. The company is expected to report its next financial numbers in August 2023. Until then, investors should carefully evaluate the company's financial position and consider their investment options wisely.






 

Helius Medical Technologies Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com